Nath Bio-Genes (India) Ltd. (IN:NATHBIOGEN)
:NATHBIOGEN
Want to see IN:NATHBIOGEN full AI Analyst Report?
Top Page
Nath Bio-Genes (India) Ltd.
(NATHBIOGEN)
Select Model
Select Model
Rating:60Neutral
Price Target:
₹206.00
▲(29.72% Upside)
Action:ReiteratedDate:05/01/26
The score is primarily supported by solid underlying financial performance (profitability and growth with manageable leverage), but is held back by expensive valuation (high P/E with modest yield) and overbought technical conditions despite an overall uptrend.
Positive Factors
Revenue Growth
Sustained ~25% revenue growth signals robust demand for seed products and effective market penetration. Over 2-6 months this supports scaling production, strengthens distributor relationships, funds incremental R&D and seed multiplication, and underpins durable top-line momentum.
Negative Factors
Cash Flow Variability
Variable free cash flow conversion creates uncertainty in liquidity for a seasonal seed business. Inconsistent cash generation can constrain working capital for seed multiplication, delay capex or R&D spending, and increase reliance on short-term funding during lean quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained ~25% revenue growth signals robust demand for seed products and effective market penetration. Over 2-6 months this supports scaling production, strengthens distributor relationships, funds incremental R&D and seed multiplication, and underpins durable top-line momentum.
Read all positive factors
Nath Bio-Genes (India) Ltd. (NATHBIOGEN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹3.72B
Dividend Yield1.26%
Average Volume (3M)2.58K
Price to Earnings (P/E)46.0
Beta (1Y)1.20
Revenue Growth25.14%
EPS Growth9.78%
CountryIN
Employees423
SectorConsumer Defensive
Sector Strength42
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)0.84
Shares Outstanding19,004,000
10 Day Avg. Volume2,256
30 Day Avg. Volume2,581
Financial Highlights & Ratios
PEG Ratio-3.00
Price to Book (P/B)0.47
Price to Sales (P/S)0.82
P/FCF Ratio31.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nath Bio-Genes (India) Ltd. Business Overview & Revenue Model
Company Description
Nath Bio-Genes (India) Limited engages in the production, processing, and marketing of hybrid and GM seeds in India and internationally. It operates in two segments, Agricultural Activities and Trading Activities. The company offers seeds for cere...
How the Company Makes Money
The company primarily makes money by selling crop seeds to the agricultural market. Its core revenue stream is the sale of proprietary and licensed seed products (commonly including hybrid and improved varieties), distributed through agricultural ...
Nath Bio-Genes (India) Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
68
Positive
Cash Flow
65
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.16B | 3.65B | 2.48B | 3.01B | 2.78B | 3.07B |
| Gross Profit | 2.18B | 2.29B | 1.03B | 1.67B | 1.54B | 1.71B |
| EBITDA | 629.40M | 497.98M | 536.39M | 488.91M | -497.06M | 684.33M |
| Net Income | 462.29M | 386.00M | 396.19M | 350.11M | -673.38M | 556.62M |
Balance Sheet | ||||||
| Total Assets | 10.14B | 10.26B | 8.80B | 7.93B | 7.42B | 7.90B |
| Cash, Cash Equivalents and Short-Term Investments | 1.59B | 888.99M | 774.10M | 379.90M | 41.68M | 292.11M |
| Total Debt | 1.55B | 1.23B | 1.10B | 1.05B | 929.59M | 965.67M |
| Total Liabilities | 3.34B | 3.82B | 2.70B | 2.20B | 2.00B | 1.76B |
| Stockholders Equity | 6.80B | 6.44B | 6.10B | 5.73B | 5.42B | 6.13B |
Cash Flow | ||||||
| Free Cash Flow | -1.10B | 96.61M | 478.18M | 358.18M | -39.70M | -104.86M |
| Operating Cash Flow | -1.09B | 175.81M | 745.94M | 383.67M | 170.46M | 11.13M |
| Investing Cash Flow | -11.48M | -39.62M | -274.01M | -28.84M | -198.66M | -102.82M |
| Financing Cash Flow | 216.74M | -21.30M | -77.78M | -16.68M | -222.27M | 164.01M |
Nath Bio-Genes (India) Ltd. Technical Analysis
Positive
158.80
Price Trends
147.08
Positive
149.40
Positive
164.35
Positive
Market Momentum
6.26
Negative
68.34
Neutral
70.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NATHBIOGEN, the sentiment is Positive. The current price of 158.8 is above the 20-day moving average (MA) of 146.23, above the 50-day MA of 147.08, and below the 200-day MA of 164.35, indicating a bullish trend. The MACD of 6.26 indicates Negative momentum. The RSI at 68.34 is Neutral, neither overbought nor oversold. The STOCH value of 70.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NATHBIOGEN.
Nath Bio-Genes (India) Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹96.72B | 13.57 | ― | 1.02% | 32.28% | 131.62% | |
64 Neutral | ₹49.16B | 33.24 | ― | 0.17% | 0.87% | -4.76% | |
64 Neutral | ₹51.60B | 23.07 | ― | 0.92% | 8.79% | 46.91% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
60 Neutral | ₹3.72B | 46.03 | ― | 1.26% | 25.14% | 9.78% | |
59 Neutral | ₹20.27B | 49.77 | ― | 0.71% | 8.29% | 5.97% | |
56 Neutral | ₹17.33B | 21.94 | ― | 0.43% | 33.50% | 77.45% |
* Consumer Defensive Sector Average
IN:NATHBIOGEN
Nath Bio-Genes (India) Ltd.
196.00
34.96
21.71%
IN:DHANUKA
Dhanuka Agritech Limited
1,078.65
-219.99
-16.94%
IN:INSECTICID
Insecticides (India) Limited
696.70
0.22
0.03%
IN:IPL
India Pesticides Ltd.
150.45
6.57
4.57%
IN:RALLIS
Rallis India Limited
265.35
25.88
10.81%
IN:SHARDACROP
Sharda Cropchem Ltd.
1,072.05
519.04
93.86%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.